# Melissa officinalis L. (Lemon Balm): An Integrative Review of Phytochemistry and Evidence from Preclinical Research to Clinical Studies

**Authors:** Ioan-Alexandru Cîmpeanu, Casiana Boru, Cristina Adriana Dehelean, Sergio Liga, Raluca Mioara Cosoroabă, Simona Ardelean, Roxana Popescu, Daliborca Vlad

PMC · DOI: 10.3390/plants15040650 · 2026-02-19

## TL;DR

Lemon balm has diverse bioactivities, but its effects depend heavily on preparation methods, with consistent evidence for anxiety and sleep benefits.

## Contribution

This review integrates lemon balm's phytochemistry with preclinical and clinical findings to guide future standardized research.

## Key findings

- Lemon balm consistently shows antioxidant and anti-inflammatory effects across preclinical models.
- Clinical trials support its use for anxiety, stress, and sleep-related outcomes.
- Evidence for other uses remains inconsistent due to preparation variability.

## Abstract

Melissa officinalis L. (lemon balm) is a Lamiaceae species widely used in traditional and contemporary herbal practice, yet its reported bioactivities are strongly preparation-dependent, reflecting variability between polyphenol-rich extracts and volatile essential-oil fractions. This integrative review links phytochemistry with recent preclinical findings and available clinical evidence. Across model systems, lemon balm most consistently shows antioxidant and anti-inflammatory signatures, with additional domain-specific signals reported in neurobehavioral, cardiometabolic, gastrointestinal, and dermatological models; however, comparability is limited by heterogeneous plant parts, extraction procedures, and chemical standardization. Preclinical findings were organized by biological domain, whereas clinically, the most consistent signals are observed for symptom-oriented endpoints, particularly anxiety/stress and sleep-related outcomes reported in controlled trials, including aromatherapy studies, while evidence for other indications remains mixed or insufficiently confirmed. Overall, the evidence supports continued development of chemically characterized, standardized preparations and mechanism-informed trials with harmonized outcomes and robust safety reporting to improve translational interpretability.

## Linked entities

- **Diseases:** anxiety (MONDO:0005618)

## Full-text entities

- **Genes:** Mpo (myeloperoxidase) [NCBI Gene 303413], Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}, Cat (catalase) [NCBI Gene 24248] {aka CS1, Cas1, Cat01, Catl, Cs-1}
- **Diseases:** rheumatoid arthritis (MESH:D001172), stress (MESH:D000079225), I/R injury (MESH:D015427), muscle cramps (MESH:D009120), colorectal cancer (MESH:D015179), hypertension (MESH:D006973), shortness (MESH:C537327), myocardial ischemia (MESH:D017202), gastrointestinal complaints (MESH:D005767), diabetic neuropathy (MESH:D003929), ulcer (MESH:D014456), vascular dysfunction (MESH:D002561), cytotoxicity (MESH:D064420), hypercholesterolemia (MESH:D006937), bowel dysfunction (MESH:D015212), breast cancer (MESH:D001943), depression (MESH:D003866), type 2 diabetes (MESH:D003924), neuronal (MESH:D009410), gastric injury (MESH:D013272), dry mouth (MESH:D014987), dementia (MESH:D003704), constipation (MESH:D003248), hypersensitivity (MESH:D004342), CIPN (MESH:D010523), erythema (MESH:D004890), memory deficits (MESH:D008569), cognitive deficits (MESH:D003072), Nervous (MESH:D009422), melanoma (MESH:D008545), fibrosis (MESH:D005355), injury to (MESH:D014947), inflammation (MESH:D007249), gastrointestinal symptom (MESH:D012817), headache (MESH:D006261), mitochondrial dysfunction (MESH:D028361), Pain (MESH:D010146), anhedonia (MESH:D059445), sleep disturbance (MESH:D012893), ischemic (MESH:D002545), IBS (MESH:D053560), diabetes (MESH:D003920), stable angina (MESH:D060050), cancer (MESH:D009369), irritability (MESH:D001523), Alzheimer's disease (MESH:D000544), edema (MESH:D004487), Anxiety (MESH:D001007), nausea (MESH:D009325), obese (MESH:D009765), hypoxic (MESH:D002534), visceral pain (MESH:D059265), weight gain (MESH:D015430), diarrhea (MESH:D003967), emotional distress (MESH:D012128), psoriasis (MESH:D011565), ischemia (MESH:D007511), metabolic disorder (MESH:D008659), lability (MESH:D005166), hypoxia (MESH:D000860)
- **Chemicals:** 1,3-butylene glycol (MESH:C028491), Iridoids (MESH:D039823), graphene (MESH:D006108), H2O2 (MESH:D006861), LBE (-), O2 (MESH:D013481), (E)-caryophyllene (MESH:C024714), Sildenafil (MESH:D000068677), omeprazole (MESH:D009853), nitrite (MESH:D009573), Captopril (MESH:D002216), salvianolic-acid (MESH:C568740), nigaichigoside F1 (MESH:C090725), lignans (MESH:D017705), caryophyllene oxide (MESH:C515179), monoterpenes (MESH:D039821), malondialdehyde (MESH:D008315), tannin (MESH:D013634), triterpenes (MESH:D014315), phenylalanine (MESH:D010649), starch (MESH:D013213), citric acid (MESH:D019343), glutathione (MESH:D005978), Alamar Blue (MESH:C005843), polyphenol (MESH:D059808), 4-coumaric acid (MESH:C495469), melanin (MESH:D008543), sesquiterpenes (MESH:D012717), sucrose (MESH:D013395), lipid (MESH:D008055), caffeic acid (MESH:C040048), IPP (MESH:C004809), TBARS (MESH:D017392), N-acetyl-L-cysteine (MESH:D000111), MO (MESH:D008982), Gabapentin (MESH:D000077206), 4-coumaroyl-CoA (MESH:C058644), luteolin (MESH:D047311), coumarins (MESH:D003374), ROS (MESH:D017382), citral (MESH:C007076), chlorogenic acid (MESH:D002726), glucose (MESH:D005947), Diterpenes (MESH:D004224), oleanolic acid (MESH:D009828), Flavonoid (MESH:D005419), Trolox (MESH:C010643), NaCl (MESH:D012965), DMAPP (MESH:C043060), flavanone (MESH:C028610), aminoguanidine (MESH:C004479), MVA (MESH:D008798), chalcone (MESH:D002599), carrageenan (MESH:D002351), RA (MESH:C041376), PI (MESH:D010716), mefenamic acid (MESH:D008528), MDA (MESH:D015104), quercetin (MESH:D011794), Losartan (MESH:D019808)
- **Species:** Melissa officinalis (common balm, species) [taxon 39338], Rattus norvegicus (brown rat, species) [taxon 10116], Staphylococcus aureus (species) [taxon 1280], Homo sapiens (human, species) [taxon 9606], Actinopterygii (fishes, superclass) [taxon 7898], Escherichia coli (E. coli, species) [taxon 562], Bacillus subtilis (species) [taxon 1423], Mus musculus (house mouse, species) [taxon 10090], Pseudomonas aeruginosa (species) [taxon 287]
- **Mutations:** TRP-1, and TRP-2, with TRP
- **Cell lines:** SKH-1 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_C124), HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038), PC-3 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0035), A375 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_0132), HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), B16-F1 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0158), HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12944213/full.md

---
Source: https://tomesphere.com/paper/PMC12944213